Abstracts tagged "systemic lupus erythematosus (SLE) and therapy"

Abstract Number: 1651 • 2017 ACR/ARHP Annual Meeting
Screening in Patients at High Risk of Hydroxychloroquine Retinal Toxicity
Anna Viola Taulaigo¹, Maria Francisca Moraes-Fontes¹, Eunice Patarata², Sara Guerreiro Castro² and Arnaldo Dias-Santos³, ¹Unidade de Doenças Auto-imunes, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Lisbon, Portugal, ²Unidade de Doenças Auto-imunes, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central (CHLC), Lisbon, Portugal, Lisbon, Portugal, ³Serviço de Oftalmologia, Hospital de Santo António dos Capuchos, CHLC, Lisbon, Portugal, Lisbon, Portugal
Background/Purpose: Despite effectiveness and favourable safety profile, antimalarials have the potential to cause irreversible macular retinopathy and vision loss. Screening methods still vary among clinicians…
Abstract Number: 2567 • 2017 ACR/ARHP Annual Meeting
Type I IFN Blockade Restores Normal Transitional B Cell Development Post-Anti-CD20 Depletion
Jennie Hamilton¹, Qi Wu², PingAr Yang³, Bao Luo⁴, Shanrun Liu⁵, Huixian Hong⁶, Jun Li⁷, Hui-Chen Hsu² and John D. Mountz⁸, ¹Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ⁷Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Department of Medicine, Birmingham, AL
Background/Purpose: Application of B cell depletion therapy (BCDT) for treatment of SLE has shown promise in some patients, but some patients exhibit disease relapses. Anti-type…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].